Treating myoclonic epilepsy in children: state-of-the-art

Bibliography

• Leppik IE. Classification of the myoclonic epilepsies. Epilepsia 2003;44:2-6
   PubMedGoogle Scholar
• Striano P, Zara F. Pathophysiology of myoclonic seizures. In: Panayiotopoulos CP, editor. Atlas of epilepsy. Springer Science+Business Media, Part 5, London; 2010. p. 235-42
   Google Scholar
• Cross E. Treatment of myoclonic epilepsies. Neurol Asia 2004;9:28-9
   Google Scholar
• Dulac O, Steru D, Rey E, et al. Sodium valproate monotherapy in childhood epilepsy. Brain Dev 1986;8:47-52
   PubMed Web of Science ®Google Scholar
• Sundqvist A, Tomson T, Lundkvist B. Valproate as monotherapy for juvenile myoclonic epilepsy: dose-effect study. Ther Drug Monit 1998;20:149-57
   PubMedGoogle Scholar
• Atakli D, Sözüer D, Atay T, et al. Misdiagnosis and treatment in juvenile myoclonic epilepsy. Seizure 1998;7:63-6
   PubMed Web of Science ®Google Scholar
• Kleveland G, Engelsen BA. Juvenile myoclonic epilepsy: clinical characteristics, treatment and prognosis in a Norwegian population of patients. Seizure 1998;7:31-8
   PubMedGoogle Scholar
• Bourgeois B, Beaumanoir A, Blajev B, et al. Monotherapy with valproate in primary generalized epilepsies. Epilepsia 1987;2:S8-11
   Google Scholar
• Covanis A, Gupta AK, Jeavons PM. Sodium valproate: monotherapy and polytherapy. Epilepsia 1982;23:693-720
   PubMed Web of Science ®Google Scholar
• Chateauvieux S, Morceau F, Dicato M, Diederich M. Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol 2010;2010:479364
   PubMed Web of Science ®Google Scholar
• Wlodarczyk BJ, Palacios AM, George TM, Finnell RH. Antiepileptic drugs and pregnancy outcomes. Am J Med Genet A 2012;158A:2071-90
   PubMed Web of Science ®Google Scholar
• Striano P, Striano S. New and investigational antiepileptic drugs. Expert Opin Investig Drugs 2009;18:1875-84
   PubMed Web of Science ®Google Scholar
• Riss J, Cloyd J, Gates J, Collins S. Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand 2008;118:69-86
   PubMed Web of Science ®Google Scholar
• Mikkelsen B, Birket-Smith E, Bradt S, et al. Clonazepam in the treatment of epilepsy. A controlled clinical trial in simple absences, bilateral massive epileptic myoclonus, and atonic seizures. Arch Neurol 1976;33:322-5
   PubMedGoogle Scholar
• Obeso JA. Therapy of myoclonus. Clin Neurosci 1995-1996;3:253-7
   PubMedGoogle Scholar
• Yamatogi Y, Ohtahara S, Shigematsu H, et al. Single blind comparative study of clobazam with clonazepam in intractable childhood epilepsies. J Jpn Epilepsy Soc 1997;15:110-21
   Google Scholar
• Farrell K. Benzodiazepines in the treatment of children with epilepsy. Epilepsia 1986;27:S45-51
   PubMed Web of Science ®Google Scholar
• Biton V, Sackellares JC, Vuong A, et al. Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures. Neurology 2005;65:1737-43
   PubMed Web of Science ®Google Scholar
• Buchanan N. The use of lamotrigine in juvenile myoclonic epilepsy. Seizure 1996;5:149-51
   PubMed Web of Science ®Google Scholar
• Bergey GK. Evidence-based treatment of idiopathic generalized epilepsies with new antiepileptic drugs. Epilepsia 2005;46:161-8
   PubMed Web of Science ®Google Scholar
• Prasad A, Kuzniecky RI, Knowlton RC, et al. Evolving antiepileptic drug treatment in juvenile myoclonic epilepsy. Arch Neurol 2003;60:1100-5
   PubMedGoogle Scholar
• Morris G, Hammer A, Kustra R, Messenheimer J. Lamotrigine for patients with JME following prior treatment with valproate: results of an open-label study. Epilepsy Behavior 2004;5:509-12
   PubMedGoogle Scholar
• Genton P, Gelisse P, Crespel A. Lack of efficacy and potential aggravation of myoclonus with lamotrigine in Unverricht-Lundborg disease. Epilepsia 2006;47:2083-5
   PubMed Web of Science ®Google Scholar
• Guerrini R, Dravet C, Genton P, et al. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 1998;39:508-12
   PubMed Web of Science ®Google Scholar
• Striano P, Striano S, Minetti C, Zara F. Refractory, life-threatening status epilepticus in a 3-year-old girl. Lancet Neurol 2008;7:278-84
   PubMed Web of Science ®Google Scholar
• Crespel A, Genton P, Berramdane M, et al. Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies. Neurology 2005;65:762-4
   PubMed Web of Science ®Google Scholar
• Choi H, Morrell MJ. Review of lamotrigine and its clinical applications in epilepsy. Expert Opin Pharmacother 2003;4(2):243-51
   PubMed Web of Science ®Google Scholar
• Verrotti A, D'Adamo E, Parisi P, et al. Levetiracetam in childhood epilepsy. Paediatr Drugs 2010;12:177-86
   PubMedGoogle Scholar
• Noachtar S, Andermann E, Meyvisch P, N166 Levetiracetam Study Group. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology 2008;70:607-16
   PubMed Web of Science ®Google Scholar
• Berkovic SF, Knowlton RC, Leroy RF, et al. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology 2007;69:1751-60
   PubMed Web of Science ®Google Scholar
• Labate A, Colosimo E, Gambardella A, et al. Levetiracetam in patients with generalised epilepsy and myoclonic seizures: an open label study. Seizure 2006;15:214-18
   PubMed Web of Science ®Google Scholar
• Specchio LM, Gambardella A, Giallonardo AT, et al. Open label, long-term, pragmatic study on levetiracetam in the treatment of juvenile myoclonic epilepsy. Epilepsy Res 2006;71:32-9
   PubMed Web of Science ®Google Scholar
• Belcastro V, Costa C, Galletti F, et al. Rapid effect of levetiracetam in a case of juvenile myoclonic epilepsy. Epilepsy Beh 2009;14:269-70
   PubMedGoogle Scholar
• Kasteleijn-Nolst Trenité DG, Marescaux C, Stodieck S, et al. Photosensitive epilepsy: a model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam. Epilepsy Res 1996;25:225-30
   PubMed Web of Science ®Google Scholar
• Striano P, Sofia V, Capovilla G, et al. A pilot trial of levetiracetam in eyelid myoclonia with absences (Jeavons syndrome). Epilepsia 2008;49:425-30
   PubMed Web of Science ®Google Scholar
• Striano P, Coppola A, Pezzella M, et al. An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy. Neurology 2007;69:250-4
   PubMed Web of Science ®Google Scholar
• Specchio N, Balestri M, Striano P, et al. Efficacy of levetiracetam in the treatment of drug-resistant Rett syndrome. Epilepsy Res 2010;88:112-17
   PubMedGoogle Scholar
• Striano P, Manganelli F, Boccella P, et al. Levetiracetam in patients with cortical myoclonus: a clinical and electrophysiological study. Mov Disord 2005;20:1610-14
   PubMed Web of Science ®Google Scholar
• Faught E, Wilder BJ, Ramsay RE, et al. Topiramate placebo-controlled dose ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Neurology 1996;46:1684-90
   PubMed Web of Science ®Google Scholar
• Biton V, Montouris GD, Ritter F, et al. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Neurology 1999;52:1330-7
   PubMed Web of Science ®Google Scholar
• Arroyo S, Dodson WE, Privitera MD, et al. Randomized dose controlled study of topiramate as first-line therapy in epilepsy. Acta Neurol Scand 2005;112:214-22
   PubMed Web of Science ®Google Scholar
• Nicolson A, Appleton RE, Chadwick DW, Smith DF. The relationship between treatment with valproate, lamotrigine, and topiramate and the prognosis of the idiopathic generalised epilepsies. J Neurol Neurosurg Psychiatry 2004;75:75-9
   PubMed Web of Science ®Google Scholar
• Puri V, Ness S, Sattaluri SJ, et al. Long-term open-label study of adjunctive topiramate in infants with refractory partial-onset seizures. J Child Neurol 2011;10:1271-83
   Google Scholar
• Glauser TA, Pellock JM. Zonisamide in pediatric epilepsy: review of the Japanese experience. J Child Neurol 2002;17:87-96
   PubMed Web of Science ®Google Scholar
• Kothare SV, Valencia I, Khurana DS, et al. Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy. Epileptic Disord 2004;6:267-70
   PubMed Web of Science ®Google Scholar
• Vossler D, Conry J, Murphy J, et al. Zonisamide for the treatment of myoclonic seizures in progressive myoclonic epilepsy: an open-label study. Epileptic Disord 2008;10:31-4
   PubMed Web of Science ®Google Scholar
• Italiano D, Pezzella M, Coppola A, et al. A pilot open-label trial of zonisamide in Unverricht-Lundborg disease. Mov Disord 2011;26:341-3
   PubMed Web of Science ®Google Scholar
• Coppola G, Grosso S, Verrotti A, et al. Zonisamide in children and young adults with refractory epilepsy: an open label, multicenter Italian study. Epilepsy Res 2009;83:112-16
   PubMed Web of Science ®Google Scholar
• Tan HJ, Martland TR, Appleton RE, Kneen R. Effectiveness and tolerability of zonisamide in children with epilepsy: a retrospective review. Seizure 2010;19:31-5
   PubMed Web of Science ®Google Scholar
• Genton P, Gelisse P, Thomas P, Dravet C. Do carbamazepine and phenytoin aggravate juvenile myoclonic epilepsy? Neurology 2000;55:1106-9
   PubMed Web of Science ®Google Scholar
• Genton P, McMenamin J. Aggravation of seizures by antiepileptic drugs: what to do in clinical practice. Epilepsia 1998;39:S26-9
   PubMed Web of Science ®Google Scholar
• Wheless JW, Sankar R. Treatment strategies for myoclonic seizures and epilepsy syndromes with myoclonic seizures. Epilepsia 2003;44:s27-37
   PubMed Web of Science ®Google Scholar
• Biraben A, Allain H, Scarabin JM, et al. Exacerbation of juvenile myoclonic epilepsy with lamotrigine. Neurology 2000;55:175
   Web of Science ®Google Scholar
• Carrazana EJ, Wheeler SD. Exacerbation of juvenile myoclonic epilepsy with lamotrigine. Neurology 2001;56:1424-5
   PubMed Web of Science ®Google Scholar
• Capovilla G, Beccaria F, Veggiotti P, et al. Ethosuximide is effective in the treatment of epileptic negative myoclonus in childhood partial epilepsy. J Child Neurol 1999;14:395-400
   PubMedGoogle Scholar